Wang et al (87) reported that a 39-year-old patient with advanced ALK-rearranged NSCLC developed tumor lysis syndrome after 22-day therapy of brigatinib, whose serum creatinine rose from 73 μmol/L to 320.2 μmol/L over 22 days of brigatinib treatment. Here, ALK is linked to non-small cell lung carcinoma.